Literature DB >> 35259492

Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment.

Mehri Monavarian1, Amal Taher Elhaw2, Priscilla W Tang2, Zaineb Javed2, Zainab Shonibare1, Carly Bess Scalise3, Rebecca Arend3, Mohit Kumar Jolly4, Mary Kathryn Sewell-Loftin5, Nadine Hempel6, Karthikeyan Mythreye7.   

Abstract

The ascites ecosystem in ovarian cancer is inhabited by complex cell types and is bathed in an environment rich in cytokines, chemokines, and growth factors that directly and indirectly impact metabolism of cancer cells and tumor associated cells. This milieu of malignant ascites, provides a 'rich' environment for the disease to thrive, contributing to every aspect of advanced ovarian cancer, a devastating gynecological cancer with a significant gap in targeted therapeutics. In this perspective we focus our discussions on the 'acellular' constituents of this liquid malignant tumor microenvironment, and how they influence metabolic pathways. Growth factors, chemokines and cytokines are known modulators of metabolism and have been shown to impact nutrient uptake and metabolic flexibility of tumors, yet few studies have explored how their enrichment in malignant ascites of ovarian cancer patients contributes to the metabolic requirements of ascites-resident cells. We focus here on TGF-βs, VEGF and ILs, which are frequently elevated in ovarian cancer ascites and have all been described to have direct or indirect effects on metabolism, often through gene regulation of metabolic enzymes. We summarize what is known, describe gaps in knowledge, and provide examples from other tumor types to infer potential unexplored roles and mechanisms for ovarian cancer. The distribution and variation in acellular ascites components between patients poses both a challenge and opportunity to further understand how the ascites may contribute to disease heterogeneity. The review also highlights opportunities for studies on ascites-derived factors in regulating the ascites metabolic environment that could act as a unique signature in aiding clinical decisions in the future.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ascites; Growth factors; Metabolism; Ovarian cancer; TGF-β; VEGF

Year:  2022        PMID: 35259492      PMCID: PMC9441472          DOI: 10.1016/j.semcancer.2022.03.004

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   17.012


  2 in total

1.  A novel form of docetaxel polymeric micelles demonstrates anti-tumor and ascites-inhibitory activities in animal models as monotherapy or in combination with anti-angiogenic agents.

Authors:  Leilei Guo; Xiaokang Qin; Liting Xue; Janine Y Yang; Yumei Zhang; Shunwei Zhu; Gang Ye; Renhong Tang; WenQing Yang
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

Review 2.  Nanomedicine Strategies for Heating "Cold" Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC.

Authors:  Yuqi Yang; Tianjiao Zhao; Qiaohui Chen; Yumei Li; Zuoxiu Xiao; Yuting Xiang; Boyu Wang; Yige Qiu; Shiqi Tu; Yitian Jiang; Yayun Nan; Qiong Huang; Kelong Ai
Journal:  Adv Sci (Weinh)       Date:  2022-07-22       Impact factor: 17.521

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.